We employ approximately 2,600 scientists and regulatory staff. Our focus on innovation demonstrates our commitment to providing the therapeutic equivalent of brand name drugs, at affordable prices, and designing enhanced versions of drugs.
We were the first generics company to patent a new drug.
We have developed a novel heat stable antiretroviral (ARV) formulation so that our products can be distributed and used in warm climates where refrigeration is not widely available.
At Mylan, we innovate to satisfy unmet needs. That's why you can confidently choose Mylan.